Latest broker research reports with buy, hold and sell recommendations along with share price targets forecast and upside.
Browse thousands of reports and search by company or broker.
The company has shown impressive YoY revenue growth and improving profitability and margin, particularly aided by the BFSI and healthcare sectors. With expectations of double-digit revenue growth and EBITDA margin between 20-22% in the future, the company's prospects are bright. New transformational initiatives and investments in the GenAI business unit are expected to boost profitability. Additionally, the company's strong performance in the BFSI and healthcare segments, driven by new client acquisitions and a healthy pipeline, will likely...
IndusInd Bank recorded subdued financial results in Q1FY26. However, it *over or under performance to benchmark index demonstrated resilience as it returned to profitability and its core operations stabilised. It is also aiming for a consistent and predictable improvement in financial metrics every quarter. Leadership transition remains on track, with CEO recommendations submitted for regulatory approval. Demand for vehicle loans continues to hold steady, supported by recovery in rural markets driven by a strong monsoon season and increased government spending on infrastructure. The bank's...
A strong order pipeline, deeper client engagement, a focus on cost optimisation through the Hence, we reiterate the rating to HOLD on the stock with a revised target price of Rs. 5,646 using a target multiple of 28x P/E on FY27E adjusted EPS....
The quarter was supported by a well-diversified content slate and improved admissions. Near-term risks include external disruptions and regulatory overhangs like Karnataka pricing. However, a strong rebound in Hollywood content, select Bollywood hits and stable regional traction offer comfort. The company is well-positioned to...
We have revised our FY26E/FY27E EPS estimates by -4.4%/-9.0% factoring in a miss in Q1FY26 performance, slower-than-expected recovery in exports due to prolonged customer destocking, and regulatory headwinds in biologicals that have curtailed domestic growth.
Management guides for single-digit growth in FY26E for PV/CV, with Q2FY26E recovery on a low base. PV growth is expected to remain in the range of ~1.0–2.0% in FY26E amid muted sentiment, with Altroz/Tiago refresh aiding hatch share recovery, and Sierra EV/Harrier EV launches boosting UV positioning.
at 50% discount to consensus target market value. We recently met the management of Finolex Industries (FNXP) to gauge volume growth outlook, market share dynamics, PVC resin availability, and price trends post DGTR's final findings on ADD on PVC resin. The company reiterated its 10% volume growth guidance in Pipes & Fittings (P&F) for FY26 and expects margin improvement ahead. We believe FNXP stands to benefit from 1) imposition of ADD on PVC resin given its backward integration, 2) GST rate revision on agri pipes, 3) expanding dealer/distribution network, and 4) gradual expansion in...
